Janssen Korea Faces Possible Six-Month Production Suspension
This article was originally published in PharmAsia News
Johnson & Johnson's Janssen Korea unit has been found to have violated several manufacturing regulations during production of its Tylenol children's syrup that contained excessive amounts of acetaminophen API.
You may also be interested in...
A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.